Search - tctmd.com

Displaying 1 - 20 of 64

Sort: Relevancy | Date

Presentation TCT 2025

Abluminus Sirolimus DES+ vs. Everolimus-Eluting Stents in Patients with Diabetes Mellitus: Final 2-Year Results of the ABILITY Global Study

Presenter: Alexandre Abizaid

October 25, 2025

Presentation TCT 2024

TCT 427: Comparison of Clinical Outcomes Between Second Generation Zotarolimus- Versus Everolimus-Eluting Stents up to 10-Year Follow-up

Presenter: Woo Jin Ahn

October 29, 2024

Presentation TCT 2023

TCT 677: Direct Comparison of Zotarolimus Eluting Stents vs Everolimus Eluting Stents Stratified by Follow-ups: An Updated Meta-analysis of Randomized Controlled Trials

Presenter: Usman Naseer

October 25, 2023

Presentation TCT 2023

Long-Term Outcomes with Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents in Patients With ST-Segment Elevation Myocardial Infarction: 5-Year Follow-up of the Biostemi Randomized Trial

Presenter: Juan Iglesias

October 25, 2023

Presentation TCT 2023

Polymer-Free Amphilimus-Eluting Stents vs. Biodegradable-Polymer Everolimus-Eluting Stents in All-Comers Undergoing PCI: 1-Year Results of the PARTHENOPE Trial

Presenter: Giovanni Esposito

October 25, 2023

Presentation TCT 2022

Everolimus-Eluting Stents or Bypass Surgery for Mutivessel Coronary Artery Disease: 10-Year Outcomes of Multicenter Randomized Controlled BEST Trial

Presenter: Jung-Min Ahn

September 19, 2022

Presentation TCT 2021

TIDES-ACS: Three-Year Outcomes From a Randomized Trial of Titanium Nitride Oxide-Coated Versus Everolimus-eluting Stents in Patients With Acute Coronary Syndromes

Presenter: Pasi Karjalainen

November 06, 2021

Presentation TCT 2020

TCT 276: A 'Real-World' Multi-center Registry Evaluating Safety and Clinical Performance of Biodegradable Polymer-coated Ultra-thin Everolimus-eluting Stents: 3-year Results from the PERFORM-EVER Registry

Presenter: Sridhar Kasturi, MD

October 14, 2020

Presentation TCT 2019

TCT 47: Five-Year Clinical Outcomes From Randomized Comparison of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents in Patients With Coronary Artery Disease From ABSORB China Trial

Presenter: Run-Lin Gao

September 25, 2019

Presentation TCT 2019

TCT 11: Everolimus-eluting Bioresorbable Scaffolds versus Drug-eluting Stents in Patients with Acute Myocardial Infarction – 2-Year Results of the Randomized ISAR-Absorb MI Trial

Presenter: Jens Wiebe

September 25, 2019

Presentation TCT 2018

RESET: Seven-Year Follow-up From a Randomized Trial of Sirolimus-Eluting vs Everolimus-Eluting Stents in Patients With Coronary Artery Disease

Presenter: James B. Hermiller Jr, Hiroki Shiomi

September 25, 2018

Presentation TCT 2018

TCT-1: Optimal Duration of Dual Antiplatelet Therapy After Left Main Coronary Stenting With Everolimus-Eluting Stents: Analysis From the EXCEL Trial

Presenter: Steven R. Bailey, Patrick W. Serruys, Sorin J. Brener

September 22, 2018

Presentation TCT 2018

TCT-91: Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents versus Thin Durable Polymer Everolimus-Eluting Stents in Patients Undergoing Coronary Revascularization (BIOFLOW V): Acute Coronary Syndrome Subgroup Analysis

Presenter: Alexandre Abizaid, Didier Carrié, Ariel Roguin

September 21, 2018

Presentation TCT 2017

Promus Element Everolimus-Eluting Stents: Device Iterations and Randomized/Registry Outcomes Data in Perspective

Presenter: Stephen G. Ellis, David E. Kandzari, Sigmund Silber

October 30, 2017

Presentation TCT 2017

XIENCE Everolimus-Eluting Stents: Device Iterations, Randomized/Registry Outcomes Data in Perspective and the Move to Shorter DAPT

Presenter: Stephen G. Ellis, David E. Kandzari, Tullio Palmerini

October 30, 2017

Presentation TCT 2016

Trial #1 - The Essentials of ... ABSORB III Everolimus-Eluting Bioresorbable Vascular Scaffolds vs Everolimus-Eluting Metallic Stents in Coronary Artery Disease

Presenter: Sunil V. Rao, Harvey D. White, Stephen G. Ellis

October 31, 2016

Presentation TCT 2016

EXCEL: A Prospective, Randomized Trial Comparing Everolimus-Eluting Stents and Bypass Graft Surgery in Selected Patients With Left Main Coronary Artery Disease

Presenter: Martin B. Leon, Keith G. Oldroyd, Gregg W. Stone

October 31, 2016

Presentation TCT 2016

Stent Design and Comprehensive Data Review: Platinum Chromium Everolimus-Eluting Stents - Evolution From the Fluoropolymer-Based Promus Element to the Bioabsorbable Polymer-Based Synergy

Presenter: Dean J. Kereiakes, Pieter C. Smits

October 30, 2016

Presentation TCT 2016

Stent Design and Comprehensive Data Review: Xience Cobalt Chromium Fluoropolymer-Based Everolimus-Eluting Stents

Presenter: Dean J. Kereiakes, Pieter C. Smits, Tullio Palmerini

October 30, 2016

Presentation TCT 2015

TUXEDO: A Prospective Randomized Trial of Paclitaxel-Eluting vs Everolimus-Eluting Stents in Diabetic Patients With Coronary Artery Disease

Presenter: Cindy L. Grines, Upendra Kaul

October 14, 2015

Advertisement

Abluminus Sirolimus DES+ vs. Everolimus-Eluting Stents in Patients with Diabetes Mellitus: Final 2-Year Results of the ABILITY Global Study

TCT 427: Comparison of Clinical Outcomes Between Second Generation Zotarolimus- Versus Everolimus-Eluting Stents up to 10-Year Follow-up

TCT 677: Direct Comparison of Zotarolimus Eluting Stents vs Everolimus Eluting Stents Stratified by Follow-ups: An Updated Meta-analysis of Randomized Controlled Trials

Long-Term Outcomes with Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents in Patients With ST-Segment Elevation Myocardial Infarction: 5-Year Follow-up of the Biostemi Randomized Trial

Polymer-Free Amphilimus-Eluting Stents vs. Biodegradable-Polymer Everolimus-Eluting Stents in All-Comers Undergoing PCI: 1-Year Results of the PARTHENOPE Trial

Everolimus-Eluting Stents or Bypass Surgery for Mutivessel Coronary Artery Disease: 10-Year Outcomes of Multicenter Randomized Controlled BEST Trial

TIDES-ACS: Three-Year Outcomes From a Randomized Trial of Titanium Nitride Oxide-Coated Versus Everolimus-eluting Stents in Patients With Acute Coronary Syndromes

TCT 276: A 'Real-World' Multi-center Registry Evaluating Safety and Clinical Performance of Biodegradable Polymer-coated Ultra-thin Everolimus-eluting Stents: 3-year Results from the PERFORM-EVER Registry

TCT 47: Five-Year Clinical Outcomes From Randomized Comparison of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents in Patients With Coronary Artery Disease From ABSORB China Trial

TCT 11: Everolimus-eluting Bioresorbable Scaffolds versus Drug-eluting Stents in Patients with Acute Myocardial Infarction – 2-Year Results of the Randomized ISAR-Absorb MI Trial

RESET: Seven-Year Follow-up From a Randomized Trial of Sirolimus-Eluting vs Everolimus-Eluting Stents in Patients With Coronary Artery Disease

TCT-1: Optimal Duration of Dual Antiplatelet Therapy After Left Main Coronary Stenting With Everolimus-Eluting Stents: Analysis From the EXCEL Trial

TCT-91: Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents versus Thin Durable Polymer Everolimus-Eluting Stents in Patients Undergoing Coronary Revascularization (BIOFLOW V): Acute Coronary Syndrome Subgroup Analysis

Promus Element Everolimus-Eluting Stents: Device Iterations and Randomized/Registry Outcomes Data in Perspective

XIENCE Everolimus-Eluting Stents: Device Iterations, Randomized/Registry Outcomes Data in Perspective and the Move to Shorter DAPT

Trial #1 - The Essentials of ... ABSORB III Everolimus-Eluting Bioresorbable Vascular Scaffolds vs Everolimus-Eluting Metallic Stents in Coronary Artery Disease

EXCEL: A Prospective, Randomized Trial Comparing Everolimus-Eluting Stents and Bypass Graft Surgery in Selected Patients With Left Main Coronary Artery Disease

Stent Design and Comprehensive Data Review: Platinum Chromium Everolimus-Eluting Stents - Evolution From the Fluoropolymer-Based Promus Element to the Bioabsorbable Polymer-Based Synergy

Stent Design and Comprehensive Data Review: Xience Cobalt Chromium Fluoropolymer-Based Everolimus-Eluting Stents

TUXEDO: A Prospective Randomized Trial of Paclitaxel-Eluting vs Everolimus-Eluting Stents in Diabetic Patients With Coronary Artery Disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content